Navigation Links
Sanofi and Regeneron Report Positive Preliminary Phase 2 Program Results for Anti-PCSK9 Antibody in Hypercholesterolemia
Date:11/9/2011

PARIS and TARRYTOWN, N.Y., Nov. 10, 2011 /PRNewswire/ -- Sanofi (EURONEXT: SAN and NYSE: SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced positive preliminary results from the Phase 2 study program in which patients with elevated low-density lipoprotein cholesterol (LDL-C) were treated with REGN727/SAR236553.

REGN727/SAR236553 is a novel, high-affinity, subcutaneously administered, fully-human antibody targeting PCSK9 (proprotein convertase subtilisin/kexin type 9).  Blocking the PCSK9 pathway is a novel mechanism for lowering LDL-C, the leading known risk factor for coronary artery disease.

One Phase 2 trial studied patients with heterozygous familial hypercholesterolemia (heFH) with elevated cholesterol (LDL-C>/=100mg/dL) despite lipid lowering therapy (statins with or without ezetemibe).  The objective of the study was to compare the effect of adding REGN727/ SAR236553 to the existing lipid lowering therapy in heFH patients.  In the primary efficacy analysis of the study, after 12 weeks of treatment, patients who received different dosing regimens of REGN727/SAR236553 achieved mean LDL-C reductions from baseline ranging from approximately 30% to greater than 65% depending on the dosing regimen of REGN727/SAR236553 compared to a mean reduction of 10% with placebo (p<0.05 for all dose groups).  Patients in the study are being followed for a total of 20 weeks for safety.

In this trial, REGN727/SAR236553 was generally well tolerated over 12 weeks.  There were no elevations in LFTs >3 times the upper limit of normal (ULN) and no cases of elevated CPK reported.  The most common adverse event was injection site reaction.  There were no serious adverse events on active treatment.  Full safety data from the 8-week po
'/>"/>

SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Vical Licensee Sanofi-aventis Initiates Phase 3 Trial to Reduce Amputations
2. Sanofi Pasteur Receives FDA Approval of Meningococcal Vaccine for Children
3. Sanofi Pasteur Initiates Phase II Trial of Cell Culture-Based Seasonal Influenza Vaccine
4. Sanofi Pasteur to Donate 60 Million Doses of H5N1 Vaccine to WHO Over 3 Years for its Influenza Vaccine Global Stockpile
5. Sanofi Pasteur Shipping First Doses of Influenza Vaccine for the 2008-2009 Season in the US
6. Insulin Analogues From Novo Nordisk, Eli Lilly and Sanofi-Aventis Will Drive Growth in the Type 1 Diabetes Drug Market
7. Sanofi Aventis: People With Type 2 Diabetes Treated With LANTUS(R) and APIDRA(R) Achieved Greater Reductions in A1C Than Those Treated With Pre-mixed Insulin
8. Sanofi Pasteur Starts a Phase II Study of a Vaccine Against Clostridium Difficile
9. Sanofi Pasteur Dengue Vaccine Enters Pediatric Efficacy Clinical Study
10. Sanofi-aventis Stands Behind the Safety of Lantus(R)
11. Sanofi Pasteur Submits Supplemental Application for A(H1N1) Pandemic Vaccine to U.S. FDA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)...   , July 2, 2015 BGI ... Hong Kong has been accredited ... Kong facility is the first clinical next-generation-sequencing laboratory to ... , meeting the highest standard in clinical laboratory practices. Complementary ... 11 compliant laboratory process, and multiple ISO certifications, the ...
(Date:7/2/2015)...   Wilson Therapeutics AB , a privately-held biopharmaceutical ... its board of directors. The appointment was approved by ... 30. "We are delighted to welcome Hans ... , CEO of Wilson Therapeutics. "Hans brings significant global ... to his contributions to the Company." Hans ...
(Date:7/1/2015)... 1, 2015 The Coalition of State ... and regional professional rheumatology societies, today released the ... explored perceptions of biosimilars and the potential impact ... Biosimilars are medicines that are highly similar, ... notably different from generic medications in that it ...
Breaking Medicine Technology:BGI Receives Accreditation from the College of American Pathologists (CAP) 2Wilson Therapeutics Appoints Hans Schikan to its Board of Directors 2Survey Of Rheumatologists Nationwide Regarding Biosimilars Highlights Need For More Robust FDA Standards 2
(Date:7/2/2015)... ... July 02, 2015 , ... “ LIFX ” was featured on NewsWatch ... products available to consumers. Amanda Forstrom, a technology expert and special reporter for NewsWatch, ... versatile smart light bulbs on the market. , According to the U.S. Department of ...
(Date:7/2/2015)... PEACHTREE CITY, GA (PRWEB) , ... July 02, ... ... or field sporting the newest shades of the SIGVARIS PERFORMANCE SOCKS. Since the ... physicians, fitness experts and athletic trainers. Their significant popularity has inspired four new, ...
(Date:7/2/2015)... ... , ... Six months ahead of his 80th birthday, Don Stevenson has reached ... for the Pulmonary Hypertension Association (PHA). Stevenson began the walk in Washington State ... mid-September. He left Glasgow, Mont. yesterday morning and is making his way to Wolf ...
(Date:7/2/2015)... Diego, CA (PRWEB) , ... July 02, 2015 , ... ... and a passion for social fitness. Built to function as a lifestyle community, Active ... giving them the opportunity to network, meet, and participate in discussions or group events. ...
(Date:7/2/2015)... ... July 02, 2015 , ... ... - pipeline review 2015” provides comprehensive information on the pipeline products with ... on negative pressure wound therapy (NPWT) with 22 market data tables and ...
Breaking Medicine News(10 mins):Health News:The Most Versatile Smart Light Bulbs were featured on NewsWatch Television 2Health News:SIGVARIS is Sporting Four Brand New Colors in the Popular PERFORMANCE SOCK Product Line 2Health News:79-Year-old ‘Pacing Parson’ Passes 1,000-Mile Mark in Cross-Country Walk for Pulmonary Hypertension Association 2Health News:79-Year-old ‘Pacing Parson’ Passes 1,000-Mile Mark in Cross-Country Walk for Pulmonary Hypertension Association 3Health News:ActiveBunch.com Launches as a Social Community for People with Active Lifestyles 2Health News:Negative Pressure Wound Therapy (System, Wound Care, Tissue Cooling NPWT) Pipeline Review 2015 Market Research Report Available at RnRMarketResearch.com 2Health News:Negative Pressure Wound Therapy (System, Wound Care, Tissue Cooling NPWT) Pipeline Review 2015 Market Research Report Available at RnRMarketResearch.com 3Health News:Negative Pressure Wound Therapy (System, Wound Care, Tissue Cooling NPWT) Pipeline Review 2015 Market Research Report Available at RnRMarketResearch.com 4
... to the health threat posed by Americans, over-consumption of sodium, ... Public Health (HSPH) and The Culinary Institute of America (CIA) ... effectiveand that maximize the enjoyment people derive from food. ... sodium reduction as a critical public health priority, much as ...
... ,e-visit, using images sent via Internet, study finds , ... who had online follow-up visits with their dermatologist had ... a new study finds. , The study included 121 ... follow-up visits or four in-office visits. Every six weeks, ...
... ... Energy without the stomach issues. The Company chose four test markets to evaluate adoption ... ... Energy ™ patches are newly released to the retail market. Many health conscious adults ...
... University of Illinois have identified a potential drug target ... is embedded in the membrane of neurons and other ... activates this receptor, sparking increased activity in the affected ... The new findings appear in the FASEB Journal ...
... ... Will Participate – Savings and Valuable Incentives Are Still Available , ... (Vocus) April 20, 2010 -- Toll Brothers, the ... at communities nationwide from April 24 until May 2. With the slight rise in interest ...
... ... babies. , ... April 20, 2010 -- Building on 175 years of expertise in the care for mothers ... new , , , , ,ePhilanthropy venture dedicated to supporting healthy moms, pregnancies and babies. ...
Cached Medicine News:Health News:Experts call for accelerated national sodium reduction initiatives 2Health News:Experts call for accelerated national sodium reduction initiatives 3Health News:Experts call for accelerated national sodium reduction initiatives 4Health News:Acne Patients Happy With Online Follow-Up Care 2Health News:Peoria and Baltimore Serve as Test Markets for New Spot On Energy Product 2Health News:Team finds promising new drug target for Alzheimer's disease 2Health News:Team finds promising new drug target for Alzheimer's disease 3Health News:Spring Into A New Toll Brothers Dream Home During the National Spring Sales Event April 24 - May 2 2Health News:Spring Into A New Toll Brothers Dream Home During the National Spring Sales Event April 24 - May 2 3Health News:Spring Into A New Toll Brothers Dream Home During the National Spring Sales Event April 24 - May 2 4Health News:Brigham and Women's Hospital Launches Stork Fund 2Health News:Brigham and Women's Hospital Launches Stork Fund 3
Protein-to-creatinine ratio is key to earlier detection of Kidney Disease...
... Your basic entry to ... Urine Analyzer delivers an affordable, ... test strip evaluation. With fundamental, ... Urine Analyzer keeps physician office ...
... The Clinitek 50 analyzer is an ... smaller laboratories the reliability and consistency ... better, more efficient way to obtain ... settings demand an economy of motion ...
... dual pressure sensor catheters incorporate ... slow-speed injection/guide wire, or high-speed ... for high-speed injection has two ... and an open-end pigtail extension ...
Medicine Products: